Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vascular endothelial growth factor gene therapy - Artgen Biotech

Next Previous
Drug Profile

Vascular endothelial growth factor gene therapy - Artgen Biotech

Alternative Names: Neovasculgen; PI-VEGF165; VEGF gene therapy - Artgen Biotech

Latest Information Update: 12 Feb 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Human Stem Cells Institute
  • Developer Artgen Biotech
  • Class Foot disorder therapies; Gene therapies; Ischaemic heart disorder therapies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Angiogenesis inducing agents; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial disorders
  • Phase III Diabetic foot ulcer
  • Phase II/III Interstitial cystitis

Most Recent Events

  • 11 Feb 2025 Phase-III clinical trials in Diabetic foot ulcer in Russia (IM) (NCT07391319)
  • 16 Feb 2024 Phase-II/III clinical trials in Interstitial cystitis in Russia (IM) (NCT07391306)
  • 28 Sep 2018 No recent reports of development identified for clinical-Phase-Unknown development in Diabetic-foot-ulcer in Russia (IM, Injection)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top